Results 21 to 30 of about 77,108 (288)

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports [PDF]

, 2014
Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen4 (CTLA-4), an inhibitory molecule typically expressed on T cells. Blockade of CTLA-4 induces an overall activation of T cells, including an immune-mediated anti-tumour ...
Brochez, Lieve, Cocquyt, Veronique, KRUSE, VIBEKE, Marlier, Joke, Van Belle, Simon   +4 more
core   +2 more sources

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2019
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, D. Hogg, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, L. Bastholt, J. Rizzo, Á. Balogh, A. Moshyk, F. Hodi, J. Wolchok   +30 more
semanticscholar   +1 more source

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Health and Quality of Life Outcomes, 2012
Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients.
Revicki Dennis A, van den Eertwegh Alfons JM, Lorigan Paul, Lebbe Celeste, Linette Gerald, Ottensmeier Christian H, Safikhani Shima, Messina Marianne, Hoos Axel, Wagner Samuel, Kotapati Srividya   +10 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

Frontiers in Pharmacology, 2021
Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources.
Xuezhi Hao, Aizong Shen, Bin Wu
doaj   +1 more source

Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma

Case Reports in Endocrinology, 2016
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves’ disease, however, has been rarely reported with this medication.
Umal Azmat, David Liebner, Amy Joehlin-Price, Amit Agrawal, Fadi Nabhan   +4 more
doaj   +1 more source

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

New England Journal of Medicine, 2018
BACKGROUND Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small‐cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit.
M. Hellmann, T. Ciuleanu, A. Płużański, J. Lee, G. Otterson, C. Audigier-Valette, E. Minenza, H. Linardou, S. Burgers, P. Salman, H. Borghaei, S. Ramalingam, J. Brahmer, M. Reck, K. O'Byrne, W. Geese, G. Green, Han-Cheng Chang, J. Szustakowski, P. Bhagavatheeswaran, D. Healey, Yali Fu, F. Nathan, L. Paz-Ares   +23 more
semanticscholar   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2019
BACKGROUND In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed ...
M. Hellmann, L. Paz-Ares, R. Bernabé Caro, B. Żurawski, Sang-We Kim, E. Carcereny Costa, Keunchil Park, A. Alexandru, L. Lupinacci, Emmanuel de la Mora Jimenez, H. Sakai, I. Albert, A. Vergnenègre, S. Peters, K. Syrigos, F. Barlesi, M. Reck, H. Borghaei, J. Brahmer, K. O'Byrne, W. Geese, P. Bhagavatheeswaran, S. Rabindran, Ravi S. Kasinathan, F. Nathan, S. Ramalingam   +25 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source